the Company agreed to issue and sell, in a firm commitment underwritten offering (the “Offering”) an aggregate of 592,270 shares of common stock (the “Shares”), $0.000001 par value per share (the “Co…
● predictable, single-product precision without undesired by-products. The technology delivers >99% food/pharma-grade purity, simplifying formulation and regulatory readiness. Because the process run…
● predictable, single-product precision without undesired by-products. The technology delivers >99% food/pharma-grade purity, simplifying formulation and regulatory readiness. Because the process run…
lly owned purpose built subsidiary – initially 100% owned by eXoZymes) If and when we identify a business opportunity (via a specific market application for one of our exozyme biosolutions), we plan …
Reciprocal relationship from MRK graph: Reciprocal relationship from EXOZ graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EXOZ graph: Reciprocal relationship from MRK grap…
lly owned purpose built subsidiary – initially 100% owned by eXoZymes) If and when we identify a business opportunity (via a specific market application for one of our exozyme biosolutions), we plan …